Compare JPMorgan Chase & Co (JPM) vs Novavax Inc (NVAX) Price & Performance

JPMorgan Chase (JPM) trades at $343.94, up 0.83% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.8B projected for 2026. The stock shows robust fundamentals with a P/E of 14.52 and net income margin of 33.4%, though cash flow trends indicate significant investing outflows.

Outlook remains positive with a consensus price target of $372.73, implying ~8.4% upside. Risks include geopolitical tensions affecting oil markets and cybersecurity threats highlighted in recent news. Institutional ownership is stable, supporting a moderate buy rating amid economic uncertainties discussed by CEO Jamie Dimon.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.